A Phase 2 study of atorvastatin, a competitive HMG-CoA reductase (HMGCR) inhibitor, combined with TMZ and radiation therapy for newly diagnosed GBM (NCT02029573) [96] is currently ongoing. Here, HMGCR is linked to glioblastoma.